Golden Meditech applies for listing of TDR on Taiwan Stock Exchange

Net proceeds from the TDR issue will be used for the repayment of bank loans and for the Group to establish a representative office in Taiwan. As details in respect of the TDR Issue have yet to be finalized, the Group will make further announcement as soon as should such information becomes available.

Mr. Kam Yuen, Chairman of the Group commented, "We believe the TDR issue is not only an attractive alternative for international investors, but will enable Taiwan investors, particularly those who are interested to invest in the healthcare industries in mainland China to participate and reap in the rewards from the high growth sector via investing and dealing in the Shares of the Company. This will further increase the liquidity of the Company's Shares and broaden and diversify the shareholder base of the Company.

Mr. Kam reiterated that, "The implementation of Economic Cooperation Framework Agreement will bring forth the prospects for greater symbiosis between industry counterparts in the Mainland and Taiwan. We are also confident that the TDR issue will increase public awareness of the Group and will promote the Group's corporate image in Taiwan. This will enhance our competitiveness and presence in the mainland China market and benefit our business development initiatives in Taiwan in the future, which renders the TDR Issue in the best interests of the Group and its Shareholders as a whole."